Author:
Kabadi Ami M.,Mejia-Guerra Maria Katherine,Graef John D.,Khan Sohrab Z.,Walton Eric M.,Wang Xinzhu,Gersbach Charles A.,Potter Rachael
Subject
Biomedical Engineering,Biomaterials,Medicine (miscellaneous),Bioengineering
Reference71 articles.
1. Gene editing and CRISPR in the clinic: current and future perspectives;Hirakawa;Biosci Rep,2020
2. Preclinical safety and biodistribution of CRISPR targeting SIV in non-human primates;Burdo;Gene Ther,2023
3. Vertex Press Release. Vertex and CRISPR Therapeutics Announce Authorization of the First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), by the United Kingdom MHRA for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia. https://investors.vrtx.com/news-releases/news-release-details/vertex-and-crispr-therapeutics-announce-authorization-first (Accessed 4 January 2024).
4. CRISPR technologies for precise epigenome editing;Nakamura;Nat Cell Biol,2021
5. To cut or not to cut: next-generation genome editors for precision genome engineering;Zhang;Curr Opin Biomed Eng,2023
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. The realization of CRISPR gene therapy;Nature Chemical Biology;2024-06-13